BridgeBio Pharma, Inc. (NASDAQ:BBIO)

About the company

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Sector

Health Technology

Industry

Pharmaceuticals: Generic

Employees

248

CEO

Neil Kumar

Exchange

NASDAQ

Website

http://www.bridgebio.com

$41.00M

Total Revenue

248

Employees

$4B

Market Capitalization

-12.61

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$38M

Operating Margin (in %)

Total operating margin

$-308M

Net Margin (in %)

Total net margin

$-294M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Zoetis, Inc. ZTS 66214.46 6339.00 23.73 41.22 25.41
Mylan NV MYL 8385.74 11624.00 0.74 135.17 0.54
BridgeBio Pharma, Inc. BBIO 3660.85 41.00 9.64 -12.61 -718.08
Taro Pharmaceutical Industries Ltd. TARO 2563.10 645.00 1.23 10.62 37.88
TherapeuticsMD, Inc. TXMD 353.06 58.00 -8.18 -1.81 -333.88
LifeVantage Corp. LFVN 189.90 230.00 6.36 16.03 5.06
Abeona Therapeutics, Inc. ABEO 176.70 3.00 1.80 -1.74 75.95
Kindred Biosciences, Inc. KIN 162.63 4.00 2.71 -2.38 None
Cocrystal Pharma, Inc. COCP 53.55 2.00 1.96 -0.92 -733.84
China Pharma Holdings, Inc. CPHI 26.40 10.00 3.16 -1.22 -214.63
Jaguar Health, Inc. JAGX 4.35 5.00 3.45 0.07 -887.14

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Hedge Funds Are Nibbling On BridgeBio Pharma, Inc. (BBIO)

1d ago, source: YAHOO!

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of ...

BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors

12d ago, source: YAHOO!

BridgeBio Pharma, Inc. (BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has added three new independent directors to its board: former Allergan ...

How Covid is reshaping the way clinical drug trials get done

11d ago, source: The Business Journals

Covid posed a danger for ongoing drug clinical trials, but companies and researchers have made changes on the fly. Could ...

Interesting BBIO Put And Call Options For February 2021

10d ago, source: Nasdaq

Investors in BridgeBio Pharma Inc (Symbol: BBIO) saw new options become available this week, for the February 2021 expiration ...

Brent Saunders finds life after Allergan on board at newly IPO'ed BridgeBio

12d ago, source: FiercePharma

Less than two months after Allergan was officially taken in by AbbVie, ex-CEO Brent Saunders has landed on the board of ...

BRIEF-BridgeBio Pharma's ML Bio Announces Dosing Of First Subject In Phase 1 Trial For Limb Girdle Muscular Dystrophy Type 2I

25d ago, source: Reuters

June 11 (Reuters) - BridgeBio Pharma Inc: * BRIDGEBIO PHARMA’S ML BIO SOLUTIONS ANNOUNCES DOSING OF FIRST SUBJECT IN PHASE 1 CLINICAL TRIAL OF BBP-418 FOR LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2I ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.